Scientists in Barcelona ramp up their research into retrovirals and rapid diagnostic tests
Various media have reported on studies addressing COVID-19 to be undertaken by several research centres in Catalonia. Among the groups involved is IRB Barcelona’s Structural Bioinformatics and Network Biology Lab, headed by Patrick Aloy. IRB Barcelona is one of eight research centres chosen by the European Commission to study new approaches to treat and diagnose COVID-19 and thus halt the spread of the virus.
Furthermore, NostrumBiodiscovery, cofounded by IRB Barcelona researcher Modesto Orozco, is collaborating with the Barcelona Supercomputing Center–Centro Nacional de Supercomputación (BSC-CNS) in another EC project. In this regard, the project aims to use cutting-edge biocomputation to support the intelligent design of drugs to treat COVID-19.
Link to: eldiario.es
Link to: El Confidencial
Link to: EFE
Link to: La Vanguardia
Link to: 20minutos
Related content
News
Several media have reported on the collaboration of Nostrum Biodiscovery, a company cofounded by IRB Barcelona researcher Modesto Orozco, with Grifols and IrsiCaixa. This spin-off company from IRB Barcelona will contribute to research into COVID-19 by providing data that will facilitate the intelligent design of drugs in silico for the treatment of coronavirus.
La Vanguardia has devoted an article to the Senén Vilaró Prize for the best innovative company, which has recently been awarded to Nostrum Biodiscovery (NBD). This prize acknowledges the capacity of the technology developed by this company to allow pharmaceutical companies to speed up drug discovery and reduce the costs involved.
Diario de Sevilla, Granada Hoy, La Sexta, Phys, US Weekly, among other national and international media, have published articles about a study by researchers led by Fran Supek, head of the Genome Data Science laboratory at IRB Barcelona, in which they developed a machine learning method to predict unknown gene functions of microbes.
Link to La Sexta
